Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
Genmab shares surged to an all-time high following a successful phase 3 clinical trial for its experimental cancer drug petosemtamab. When combined with Merck's therapy Keytruda, the bispecific treatment cut the risk of death by 50 percent compared to Keytruda alone in head and neck cancer patients. The positive readout triggered an eight billion dollar market valuation jump for Genmab. Financial analysts characterized the trial results as an exceedingly positive early survival win and a hat trick for the drugmaker.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Genmab stock surged to a record high after its cancer drug trial met primary goals.
- ✓ The experimental cancer drug petosemtamab combined with Merck's Keytruda reduced the risk of death by 50 percent compared with Keytruda alone.
- ✓ The late-stage trial focused on a form of head and neck cancer.
What changed
Genmab reported positive phase 3 trial results showing its experimental bispecific drug combined with Keytruda significantly reduced the risk of death in head and neck cancer patients.
Live updates
-
Genmab Stock Hits Record High After Phase 3 Cancer Trial Success
Genmab shares surged to an all-time high following a successful phase 3 clinical trial for its experimental cancer drug petosemtamab. When combined with Merck's therapy Keytruda, the bispecific treatment cut the risk of death by 50 percent compared to Keytruda alone in head and neck cancer patients. The positive readout triggered an eight billion dollar market valuation jump for Genmab. Financial analysts characterized the trial results as an exceedingly positive early survival win and a hat trick for the drugmaker.
Why it matters
The successful trial validates a major acquisition strategy for Genmab, reflecting strong commercial potential in competitive oncology markets. The combination therapy targets head and neck cancer, positioning the medicine as a potential new standard of care. Market response highlights high investor demand for breakthrough oncology assets meeting primary clinical endpoints.
What is confirmed
- Genmab stock surged to a record high after its cancer drug trial met primary goals.
- The experimental cancer drug petosemtamab combined with Merck's Keytruda reduced the risk of death by 50 percent compared with Keytruda alone.
- The late-stage trial focused on a form of head and neck cancer.
What to watch next
- Further regulatory filings and progression-free survival data from the phase 3 trial
- Detailed clinical data presentations at upcoming medical oncology congresses
confidence 100%Sources used for this update (9)
- Barron's — Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%
- Fierce Biotech — Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
- Yahoo Finance — GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know
- BioSpace — Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
- WSJ — Genmab Shares Soar on Success in Head and Neck Cancer
- MedWatch — Genmab soars as key cancer drug succeeds in late-stage trial
- www.sundaynightfutures.com — Genmab Stock Surges to Record High as Cancer Drug Slashes ...
- finance.yahoo.com — GMAB Stock Hits All-Time High After Genmab’s Cancer Drug ...
- finance.yahoo.com — Genmab soars to record highs after cancer drug succeeds in ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community